BFEC
ARCT icon

Benjamin F. Edwards & Company’s Arcturus Therapeutics ARCT Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-105
Closed -$4K – 2128
2024
Q1 		$4K Sell
105
-15
-13% -$531 ﹤0.01% 1894
2023
Q4 		$4K Buy
+120
New +$2.85K ﹤0.01% 1881

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Benjamin F. Edwards & Company's ARCT Position: Q2 2024 in Review

Benjamin F. Edwards & Company sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 105 shares — an estimated $4K sold.

Benjamin F. Edwards & Company first reported a position in ARCT in Q4 2023 and held it in 2 quarters. The position peaked at $4K in Q1 2024. 171 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • Benjamin F. Edwards & Company reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Benjamin F. Edwards & Company sold 105 Arcturus Therapeutics shares in Q2 2024, an estimated $4K.
  • Benjamin F. Edwards & Company first reported a position in Arcturus Therapeutics in Q4 2023 and held it in 2 quarters.
  • Benjamin F. Edwards & Company's Arcturus Therapeutics position peaked at $4K in Q1 2024.
  • 171 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.